Elisabeth Binder given the ACNP Eva King-Killam Research Award
The American College of Neuropsychopharmacology (ACNP) has named Elisabeth Binder, M.D., Ph.D. as the winner of the Eva King-Killam Research Award. Dr. Binder heads the Department for Translational Research at the Max Planck Institute and also serves as a Full Professor at Emory University in Atlanta. The Eva King-Killam award, presented at the 55th Annual Meeting of the ACNP in Hollywood, Florida, is presented on the basis of outstanding translational research contributions to neuropsychopharmacology.
Dr. Binder is best known for her work in which she identified molecular mechanisms that relate genetic association with disease or gene x environment interactions in the development of psychiatric disorders. She has published over 170 papers in peer-reviewed journals, many of which are the top journals in her field, and has authored or co-authored 18 book chapters. Dr. Binder has been the recipient of a number of prestigious awards from professional societies, including the Theodore Reich Young Investigator Award from the International Society of Psychiatric Genetics. She is Principal Investigator or Co-Principal Investigator on 6 European research grants, 5 grants from the National Institutes of Health, and one Templeton Foundation Grant. She serves on the editorial boards of 6 professional journals, and has given over 70 invited presentations at various universities and scientific conferences around the world.
Media contact: Erin Colladay at ([email protected]; 615-649-3074)
ACNP, founded in 1961, is a professional organization of more than 1000 leading scientists, including four Nobel Laureates. The mission of ACNP is to further research and education in neuropsychopharmacology and related fields in the following ways: promoting the interaction of a broad range of scientific disciplines of brain and behavior in order to advance the understanding of prevention and treatment of disease of the nervous system including psychiatric, neurological, behavioral and addictive disorders; encouraging scientists to enter research careers in fields related to these disorders and their treatment; and ensuring the dissemination of relevant scientific advances.